GLP1R and COVID-19: Based on non-clinical and clinical data, in 2021, Lee proposed a hypothesis that GLP-1 receptor agonists could be potential therapeutic candidates in pulmonary hypertension patients recovering from COVID-19 by regulating the right ventricular systolic pressure and pulmonary artery remodeling [87].